PDLIM7 and neoplasm: Although modern therapeutic strategy centers on destabilizing the structural integrity of lysosomal membrane using single-agent interventions, combinatorial therapy involving multiple LMP-inducing agents coupled with tumor-specific lysosomal ion channel small molecule inhibitors is yet to be documented.